DRTSW — Alpha Tau Medical Ltd.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1871321 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -13,313,000 | -22,939,000 | 108,773,000 | 4,636,000 | 39,421,000 |
| Dec 2025 | 0 | — | -12,602,000 | -12,136,000 | 105,652,000 | 12,202,000 | 28,553,000 |
| Sep 2025 | 0 | — | -10,730,000 | -11,686,000 | 104,694,000 | 3,329,000 | 27,110,000 |
| Jun 2025 | 0 | — | -9,648,000 | -10,114,000 | 110,954,000 | 11,703,000 | 24,331,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-190,136,000
Inventory
—
Receivables
$336,000
ST Investments
$60,924,000
EBIT TTM
$-42,159,000
Pretax Income TTM
$-42,506,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -42,288,000 | -42,627,000 | 105,652,000 | 28,553,000 | — | -26,681,000 |
| Dec 2024 | 0 | -36,042,000 | -31,750,000 | 86,204,000 | 23,538,000 | — | -19,783,000 |
| Dec 2023 | 0 | -35,680,000 | -29,157,000 | 107,388,000 | 22,913,000 | — | -17,958,000 |
| Dec 2022 | 0 | -32,136,000 | -33,762,000 | 120,149,000 | 14,492,000 | — | -23,879,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $154.64B | $436.64 | — |
| SYK | STRYKER CORP | $119.99B | $313.00 | — |
| MDT | Medtronic plc | $99.63B | $77.60 | — |
| BSX | BOSTON SCIENTIFIC CORP | $85.67B | $57.64 | — |
| MMM | 3M CO | $80.34B | $154.03 | — |
News headlines (Yahoo Finance, 1h cache)
Alpha Tau to Participate in May Investor Conferences
2026-05-18 12:30 · Yahoo
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
2026-05-11 14:07 · Yahoo
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Obs
2026-05-11 11:00 · Yahoo
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
2026-05-08 13:10 · Yahoo
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
2026-05-08 13:00 · Yahoo
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrol
2026-05-05 13:14 · Yahoo
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
2026-05-04 13:17 · Yahoo
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
2026-04-27 13:01 · Yahoo
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
2026-04-23 13:02 · Yahoo
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
2026-04-23 13:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.